γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum: The choroid plexus as a putative origin of CSF Aβ

Fei Liu, Zhi Qin Xue, Si Hao Deng, Xiong Kun, Xue Gang Luo, Peter R. Patrylo, Gregory M. Rose, Huaibin Cai, Robert G. Struble, Yan Cai, Xiao Xin Yan

Research output: Contribution to journalArticle

Abstract

Deposition of β -amyloid (Aβ) peptides, cleavage products of β-amyloid precursor protein (APP) by β-secretase-1 (BACE1) and γ-secretase, is a neuropathological hallmark of Alzheimer's disease (AD). γ-Secretase inhibition is a therapeutical anti-Aβ approach, although changes in the enzyme's activity in AD brain are unclear. Cerebrospinal fluid (CSF) Aβ peptides are thought to derive from brain parenchyma and thus may serve as biomarkers for assessing cerebral amyloidosis and anti-Aβ efficacy. The present study compared active γ-secretase binding sites with Aβ deposition in aged and AD human cerebrum, and explored the possibility of Aβ production and secretion by the choroid plexus (CP). The specific binding density of [3H]-L-685,458, a radiolabeled high-affinity γ-secretase inhibitor, in the temporal neocortex and hippocampal formation was similar for AD and control cases with similar ages and post-mortem delays. The CP in post-mortem samples exhibited exceptionally high [3H]-L-685,458 binding density, with the estimated maximal binding sites (Bmax) reduced in the AD relative to control groups. Surgically resected human CP exhibited APP, BACE1 and presenilin-1 immunoreactivity, and β-site APP cleavage enzymatic activity. In primary culture, human CP cells also expressed these amyloidogenic proteins and released Aβ40 and Aβ42 into the medium. Overall, our results suggest that γ-secretase activity appears unaltered in the cerebrum in AD and is not correlated with regional amyloid plaque pathology. The CP appears to be a previously unrecognised non-neuronal contributor to CSF Aβ, probably at reduced levels in AD.

Original languageEnglish (US)
Pages (from-to)1714-1725
Number of pages12
JournalEuropean Journal of Neuroscience
Volume37
Issue number10
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Amyloid Precursor Protein Secretases
Choroid Plexus
Cerebrum
Cerebrospinal Fluid
Alzheimer Disease
Binding Sites
L 685458
Amyloid beta-Protein Precursor
Presenilin-1
Amyloidogenic Proteins
Peptides
Neocortex
Amyloid Plaques
Brain
Amyloid
Hippocampus
Biomarkers
Pathology
Control Groups
Enzymes

Keywords

  • β-amyloid
  • γ-secretase
  • AD biomarker
  • Anti-Aβ therapy
  • BACE1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum : The choroid plexus as a putative origin of CSF Aβ. / Liu, Fei; Xue, Zhi Qin; Deng, Si Hao; Kun, Xiong; Luo, Xue Gang; Patrylo, Peter R.; Rose, Gregory M.; Cai, Huaibin; Struble, Robert G.; Cai, Yan; Yan, Xiao Xin.

In: European Journal of Neuroscience, Vol. 37, No. 10, 05.2013, p. 1714-1725.

Research output: Contribution to journalArticle

Liu, F, Xue, ZQ, Deng, SH, Kun, X, Luo, XG, Patrylo, PR, Rose, GM, Cai, H, Struble, RG, Cai, Y & Yan, XX 2013, 'γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum: The choroid plexus as a putative origin of CSF Aβ', European Journal of Neuroscience, vol. 37, no. 10, pp. 1714-1725. https://doi.org/10.1111/ejn.12159
Liu, Fei ; Xue, Zhi Qin ; Deng, Si Hao ; Kun, Xiong ; Luo, Xue Gang ; Patrylo, Peter R. ; Rose, Gregory M. ; Cai, Huaibin ; Struble, Robert G. ; Cai, Yan ; Yan, Xiao Xin. / γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum : The choroid plexus as a putative origin of CSF Aβ. In: European Journal of Neuroscience. 2013 ; Vol. 37, No. 10. pp. 1714-1725.
@article{b23d78c7c6b84303be6c2cd252882387,
title = "γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum: The choroid plexus as a putative origin of CSF Aβ",
abstract = "Deposition of β -amyloid (Aβ) peptides, cleavage products of β-amyloid precursor protein (APP) by β-secretase-1 (BACE1) and γ-secretase, is a neuropathological hallmark of Alzheimer's disease (AD). γ-Secretase inhibition is a therapeutical anti-Aβ approach, although changes in the enzyme's activity in AD brain are unclear. Cerebrospinal fluid (CSF) Aβ peptides are thought to derive from brain parenchyma and thus may serve as biomarkers for assessing cerebral amyloidosis and anti-Aβ efficacy. The present study compared active γ-secretase binding sites with Aβ deposition in aged and AD human cerebrum, and explored the possibility of Aβ production and secretion by the choroid plexus (CP). The specific binding density of [3H]-L-685,458, a radiolabeled high-affinity γ-secretase inhibitor, in the temporal neocortex and hippocampal formation was similar for AD and control cases with similar ages and post-mortem delays. The CP in post-mortem samples exhibited exceptionally high [3H]-L-685,458 binding density, with the estimated maximal binding sites (Bmax) reduced in the AD relative to control groups. Surgically resected human CP exhibited APP, BACE1 and presenilin-1 immunoreactivity, and β-site APP cleavage enzymatic activity. In primary culture, human CP cells also expressed these amyloidogenic proteins and released Aβ40 and Aβ42 into the medium. Overall, our results suggest that γ-secretase activity appears unaltered in the cerebrum in AD and is not correlated with regional amyloid plaque pathology. The CP appears to be a previously unrecognised non-neuronal contributor to CSF Aβ, probably at reduced levels in AD.",
keywords = "β-amyloid, γ-secretase, AD biomarker, Anti-Aβ therapy, BACE1",
author = "Fei Liu and Xue, {Zhi Qin} and Deng, {Si Hao} and Xiong Kun and Luo, {Xue Gang} and Patrylo, {Peter R.} and Rose, {Gregory M.} and Huaibin Cai and Struble, {Robert G.} and Yan Cai and Yan, {Xiao Xin}",
year = "2013",
month = "5",
doi = "10.1111/ejn.12159",
language = "English (US)",
volume = "37",
pages = "1714--1725",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - γ-Secretase binding sites in aged and Alzheimer's disease human cerebrum

T2 - The choroid plexus as a putative origin of CSF Aβ

AU - Liu, Fei

AU - Xue, Zhi Qin

AU - Deng, Si Hao

AU - Kun, Xiong

AU - Luo, Xue Gang

AU - Patrylo, Peter R.

AU - Rose, Gregory M.

AU - Cai, Huaibin

AU - Struble, Robert G.

AU - Cai, Yan

AU - Yan, Xiao Xin

PY - 2013/5

Y1 - 2013/5

N2 - Deposition of β -amyloid (Aβ) peptides, cleavage products of β-amyloid precursor protein (APP) by β-secretase-1 (BACE1) and γ-secretase, is a neuropathological hallmark of Alzheimer's disease (AD). γ-Secretase inhibition is a therapeutical anti-Aβ approach, although changes in the enzyme's activity in AD brain are unclear. Cerebrospinal fluid (CSF) Aβ peptides are thought to derive from brain parenchyma and thus may serve as biomarkers for assessing cerebral amyloidosis and anti-Aβ efficacy. The present study compared active γ-secretase binding sites with Aβ deposition in aged and AD human cerebrum, and explored the possibility of Aβ production and secretion by the choroid plexus (CP). The specific binding density of [3H]-L-685,458, a radiolabeled high-affinity γ-secretase inhibitor, in the temporal neocortex and hippocampal formation was similar for AD and control cases with similar ages and post-mortem delays. The CP in post-mortem samples exhibited exceptionally high [3H]-L-685,458 binding density, with the estimated maximal binding sites (Bmax) reduced in the AD relative to control groups. Surgically resected human CP exhibited APP, BACE1 and presenilin-1 immunoreactivity, and β-site APP cleavage enzymatic activity. In primary culture, human CP cells also expressed these amyloidogenic proteins and released Aβ40 and Aβ42 into the medium. Overall, our results suggest that γ-secretase activity appears unaltered in the cerebrum in AD and is not correlated with regional amyloid plaque pathology. The CP appears to be a previously unrecognised non-neuronal contributor to CSF Aβ, probably at reduced levels in AD.

AB - Deposition of β -amyloid (Aβ) peptides, cleavage products of β-amyloid precursor protein (APP) by β-secretase-1 (BACE1) and γ-secretase, is a neuropathological hallmark of Alzheimer's disease (AD). γ-Secretase inhibition is a therapeutical anti-Aβ approach, although changes in the enzyme's activity in AD brain are unclear. Cerebrospinal fluid (CSF) Aβ peptides are thought to derive from brain parenchyma and thus may serve as biomarkers for assessing cerebral amyloidosis and anti-Aβ efficacy. The present study compared active γ-secretase binding sites with Aβ deposition in aged and AD human cerebrum, and explored the possibility of Aβ production and secretion by the choroid plexus (CP). The specific binding density of [3H]-L-685,458, a radiolabeled high-affinity γ-secretase inhibitor, in the temporal neocortex and hippocampal formation was similar for AD and control cases with similar ages and post-mortem delays. The CP in post-mortem samples exhibited exceptionally high [3H]-L-685,458 binding density, with the estimated maximal binding sites (Bmax) reduced in the AD relative to control groups. Surgically resected human CP exhibited APP, BACE1 and presenilin-1 immunoreactivity, and β-site APP cleavage enzymatic activity. In primary culture, human CP cells also expressed these amyloidogenic proteins and released Aβ40 and Aβ42 into the medium. Overall, our results suggest that γ-secretase activity appears unaltered in the cerebrum in AD and is not correlated with regional amyloid plaque pathology. The CP appears to be a previously unrecognised non-neuronal contributor to CSF Aβ, probably at reduced levels in AD.

KW - β-amyloid

KW - γ-secretase

KW - AD biomarker

KW - Anti-Aβ therapy

KW - BACE1

UR - http://www.scopus.com/inward/record.url?scp=84878014527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878014527&partnerID=8YFLogxK

U2 - 10.1111/ejn.12159

DO - 10.1111/ejn.12159

M3 - Article

C2 - 23432732

AN - SCOPUS:84878014527

VL - 37

SP - 1714

EP - 1725

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 10

ER -